Emmaus Life Sciences reports Q3 preliminary gross sales $7M
Emmaus Life Sciences reported preliminary gross sales results of $7M for the third quarter ended September 30, 2019 compared to $6.2M for the second quarter ended June 30, 2019 based on total boxes shipped. In addition, the company achieved its highest level of monthly gross sales in 2019 with $2.6M for the month of September. "We continue to make progress in the commercialization and roll-out of Endari in the U.S., which is reflected in our preliminary gross sales results for the third quarter," said CEO Yutaka Niihara. "Furthermore, we are working with several of our key distributors in accessing additional classes of trade and/or other SCD patient groups in order to make Endari more widely available. In addition, our plans to broaden Endari's expansion throughout the global marketplace continue to move forward as well as studying the use of the same pharmaceutical-grade L-glutamine oral powder used in Endari as a new therapy for treating patients with diverticulosis and diabetes."